Read More Pharma Industry News Zervimesine development highlights regulatory complexity in dementia with Lewy bodies Zervimesine moves closer to Phase 2b as Cognition Therapeutics engages FDA. Read how regulatory complexity is shaping dementia drug development. bySoujanya RaviJanuary 30, 2026